<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842747</url>
  </required_header>
  <id_info>
    <org_study_id>V3011902</org_study_id>
    <nct_id>NCT04842747</nct_id>
  </id_info>
  <brief_title>VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study</brief_title>
  <acronym>VERU-111</acronym>
  <official_title>Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veru Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veru Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing&#xD;
      its effect on the proportion of patients who die on study (prior to Day 60).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, randomized, placebo-control, efficacy and safety study of&#xD;
      VERU-111 for the treatment of COVID-19. Subjects will receive either 9mg of VERU-111 or&#xD;
      matching placebo orally or through nasogastric tube daily for up to 21 days or until the&#xD;
      subject is discharged from the hospital, whichever comes first. The primary efficacy endpoint&#xD;
      of the study will be the proportion of subjects that die prior to Day 60.The total study&#xD;
      duration for a subject from screening to follow up visit is planned to be 62 days. In&#xD;
      addition to the safety of VERU-111, an evaluation of the efficacy of VERU-111 on SARS-CoV-2&#xD;
      (COVID-19) compared to the placebo control will be evaluated as part of the Independent Data&#xD;
      Monitoring Committee (IDMC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">March 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 5, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects in the VERU-111 treatment groups will receive standard of care, plus oral daily VERU-111 9mg for 21 days or until released from hospital. Subjects in the Placebo treatment group will receive standard of care, plus a placebo capsule for 21 days or until released from hospital.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The study will be a randomized, double-blind, placebo-controlled study. Randomization will be stratified by baseline WHO Ordinal Scale score of 4,5 and 6 such that subjects with a WHO Ordinal Scale of 4, 5 and 6 at screening are approximately equally distributed between the treatment groups. An emergency code break will be available to the investigator / pharmacist / investigational drug storage manager. This code break option in IWRS may only be disclosed in emergency situations when the identity of the trial drug must be known to the investigator in order to provide appropriate medical treatment or if required to assure safety of trial participants. If the code break for a patient is opened, the sponsor and CRO will be informed immediately via IWRS notification. The reason for the IWRS unblinding of the subject must be documented on the appropriate eCRF page along with the date and the initials of the person who broke the code.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>VERU-111 in the treatment of SARS-Cov-2 Infection</measure>
    <time_frame>Day 60</time_frame>
    <description>VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the percentage of subjects that are alive without respiratory failure at various intervals.</measure>
    <time_frame>Day 29</time_frame>
    <description>The proportion of subjects that are alive without respiratory failure at Day 15, Day 22 and Day 29. Day 29 is the key secondary end point in this study. Respiratory failure is defined as endotracheal intubation and mechanical ventilation, extracorporeal membrane oxygenation, high-flow nasal cannula oxygen delivery, noninvasive positive pressure ventilation, clinical diagnosis of respiratory failure with initiation of none of these measures only when clinical decision making is driven solely by resource limitation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>SARS-CoV Infection</condition>
  <arm_group>
    <arm_group_label>9mg of VERU-111 Oral daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9mg of VERU-111</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Capsule once daily</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in the Placebo treatment group will receive standard of care, plus a placebo capsule for 21 days or until released from hospital.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VERU-111</intervention_name>
    <description>Subjects in the VERU-111 treatment groups will receive standard of care, plus oral daily VERU-111 9mg for 21 days or until released from hospital.</description>
    <arm_group_label>9mg of VERU-111 Oral daily</arm_group_label>
    <other_name>Sabizabulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide informed consent from the subject or the subject's Legally Authorized&#xD;
             Representative (LAR)&#xD;
&#xD;
          -  Aged ≥18 years&#xD;
&#xD;
          -  Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection confirmed by&#xD;
             polymerase chain reaction (PCR) test&#xD;
&#xD;
          -  Patients with a WHO Ordinal Scale for Clinical Improvement score of 4 at high risk for&#xD;
             ARDS, must have at least one of the known comorbidities for being at high risk, such&#xD;
             as, Asthma (moderate to severe), Chronic Lung Disease, Diabetes, Hypertension, Severe&#xD;
             Obesity (BMI ≥40), 65 years of age or older, primarily reside in a nursing home or&#xD;
             long-term care facility, or immunocompromised and patients with a WHO Ordinal Scale&#xD;
             for Clinical Improvement score of 5 or 6 regardless of presence of comorbidities.&#xD;
&#xD;
          -  WHO Ordinal Scale for Clinical Improvement score of 4 (Oxygen by mask or nasal&#xD;
             prongs), 5 (Non-invasive ventilation or high-flow oxygen) or 6 (Intubation and&#xD;
             mechanical ventilation)&#xD;
&#xD;
          -  Peripheral capillary oxygen saturation (SpO2) ≤ 94% on room air at screening. If&#xD;
             patient is on oxygen therapy at the time of presentation for screening and the SpO2&#xD;
             levels were ≤94% prior to introduction to oxygen therapy with proper documentation&#xD;
             example EMT notes or ER/ED notes, then the patient is considered to have met this&#xD;
             inclusion criterion. If patient is on oxygen therapy at the time of presentation for&#xD;
             screening and the SpO2 levels prior to introduction to oxygen therapy are unknown, the&#xD;
             patient may be considered to have met this inclusion criterion if oxygen therapy is&#xD;
             removed and the SpO2 levels fall to ≤94%, then the patient is considered to have met&#xD;
             this inclusion criterion. However, removal of the oxygen therapy should only be done&#xD;
             if it is considered medically reasonable&#xD;
&#xD;
          -  Subjects must agree to follow doctor's recommendation for oxygen supplementation&#xD;
&#xD;
          -  Subjects must agree to use acceptable methods of contraception:&#xD;
&#xD;
               -  If female of childbearing potential or a male subject's partner could become&#xD;
                  pregnant, use acceptable methods of contraception from the time of the first&#xD;
                  administration of study medication until 6months following administration of the&#xD;
                  last dose of study medication. Acceptable methods of contraception are as&#xD;
                  follows: Condom with spermicidal foam/gel/film/cream/suppository [i.e., barrier&#xD;
                  method of contraception], surgical sterilization (vasectomy with documentation of&#xD;
                  azospermia) and a barrier method {condom used with spermicidal&#xD;
                  foam/gel/film/cream/suppository}, the female partner uses oral contraceptives&#xD;
                  (combination estrogen/progesterone pills), injectable progesterone or subdermal&#xD;
                  implants and a barrier method (condom used with spermicidal&#xD;
                  foam/gel/film/cream/suppository)&#xD;
&#xD;
               -  If the female partner of a male subject has undergone documented tuballigation&#xD;
                  (female sterilization), a barrier method (condom used with spermicidal&#xD;
                  foam/gel/film/cream/suppository)should also be used&#xD;
&#xD;
               -  If female partner of a male subject has undergone documented placement of an&#xD;
                  intrauterine device (IUD) or intrauterine system (IUS),a barrier method (condom&#xD;
                  with spermicidal foam/gel/film/cream/suppository)should also be used&#xD;
&#xD;
          -  Subject is willing to comply with the requirements of the protocol through the end of&#xD;
             the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or allergy to colchicine&#xD;
&#xD;
          -  Pregnant or currently breast feeding&#xD;
&#xD;
          -  Participation in any other clinical trial of an experimental treatment for COVID- 19.&#xD;
             Convalescent plasma, dexamethasone and remdesivir are allowed in this study.&#xD;
&#xD;
          -  Concurrent treatment with other experimental agents with actual or possible direct&#xD;
             acting antiviral activity against COVID-19is prohibited &lt;24 hours prior to study drug&#xD;
             dosing(except standard of care). Remdesivir, dexamethasone and convalescent plasma are&#xD;
             allowed in the study.&#xD;
&#xD;
          -  Requiring ventilation + additional organ support - pressors, RRT, ECMO(WHO Ordinal&#xD;
             Scale for Clinical Improvement - Score of 7). NOTE: short term (PRN) use of pressors&#xD;
             is allowed&#xD;
&#xD;
          -  Alanine Aminotransferase (ALT) or aspartate aminotransferase(AST) &gt;3X upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  Total bilirubin &gt; ULN&#xD;
&#xD;
          -  Creatinine clearance &lt; 60 mL/min&#xD;
&#xD;
          -  Documented medical history of liver disease, including but not limited to, prior&#xD;
             diagnosis of hepatitis of any etiology, cirrhosis, portal hypertension, or confirmed&#xD;
             or suspected esophageal varices&#xD;
&#xD;
          -  Moderate to severe renal impairment&#xD;
&#xD;
          -  Hepatic impairment&#xD;
&#xD;
          -  History of hepatitis - (Hepatitis B and C) NOTE: treated and controlled hepatitis C is&#xD;
             allowed&#xD;
&#xD;
          -  Any comorbid disease or condition (medical or surgical) which might compromise the&#xD;
             hematologic, cardiovascular, endocrine, pulmonary, renal, gastrointestinal, hepatic,&#xD;
             or central nervous system; or other conditions that may interfere with the absorption,&#xD;
             distribution, metabolism or excretion of study drug, or would place the subject at&#xD;
             increased risk&#xD;
&#xD;
          -  Participants must agree to refrain from prolonged exposure to the sun or agree to use&#xD;
             at least SPF 50 on all exposed skin and protective clothing during prolonged sun&#xD;
             exposure throughout participation in this study and/or treatment with VERU-111&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barnette</last_name>
    <role>Study Chair</role>
    <affiliation>Veru Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barnette</last_name>
    <phone>800-606-9382</phone>
    <email>veruclinicaltrials@verupharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rodriguez</last_name>
    <phone>800-606-9382</phone>
    <email>veruclinicaltrials@verupharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Honor Health</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sahni Hillard</last_name>
      <phone>623-760-3711</phone>
      <email>shilliard@honorhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Vicki Daniels</last_name>
    </contact_backup>
    <investigator>
      <last_name>Michael Gordon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Bernard's Medical Center</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hailey McNew</last_name>
      <phone>870-761-2680</phone>
      <email>hdhundley@sbrmc.org</email>
    </contact>
    <investigator>
      <last_name>John Norwood</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>619-955-5246</phone>
      <email>cbarbabosa@velocityclinical.com</email>
    </contact>
    <investigator>
      <last_name>Michael Waters</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research - San Diego</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Allison Davis</last_name>
      <phone>619-567-1550</phone>
      <email>adavis@velocityclinical.com</email>
    </contact>
    <investigator>
      <last_name>Scott Overcash</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westchester General Hospital, Research Department</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerardo Masferrer</last_name>
      <phone>305-264-5254</phone>
      <email>gmasferrer@keraltyhospital.com</email>
    </contact>
    <investigator>
      <last_name>Jose Suarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James A. Haley Veterans Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Zoble</last_name>
      <phone>813-631-3671</phone>
      <email>Adam.Zoble@va.gov</email>
    </contact>
    <investigator>
      <last_name>Fabio Leonelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellstar Research Institute</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marianne Bain</last_name>
      <phone>770-324-3661</phone>
      <email>mariane.bain@wellstar.org</email>
    </contact>
    <investigator>
      <last_name>Neha Paranjape</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Harper</last_name>
      <phone>985-231-0737</phone>
      <email>kimharper@benchmarkresearch.net</email>
    </contact>
    <investigator>
      <last_name>Rick Casey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kelsey Schnackenberg</last_name>
      <phone>651-254-5304</phone>
      <email>kelsey.e.schnackenberg@healthpartners.com</email>
    </contact>
    <investigator>
      <last_name>Michael Schnaus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inspira Medical Center Mullica Hill</name>
      <address>
        <city>Mullica Hill</city>
        <state>New Jersey</state>
        <zip>08062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Vasquez</last_name>
      <phone>856-641-7921</phone>
      <email>vasquezc@ihn.org</email>
    </contact>
    <investigator>
      <last_name>M. Scott Dawson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center, Institute for Clinical Research</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Kiledjiian</last_name>
      <phone>201-541-6312</phone>
      <email>pkiledjian@holyname.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin De La Rosa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inspira Medical Center</name>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Vasquez</last_name>
      <phone>856-641-7921</phone>
      <email>vasquezc@ihn.org</email>
    </contact>
    <investigator>
      <last_name>Samaresh Dasgupta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nayeem Choudhury</last_name>
      <phone>417-379-6389</phone>
      <email>nayeem_choudhury@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Anne Lachiewicz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Stern Cardiovascular Foundation, Inc.</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian Dragutsky</last_name>
      <phone>901-504-0208</phone>
      <email>bdrag@sterncardio.com</email>
    </contact>
    <investigator>
      <last_name>John Jefferies</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional One Health</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kacy Acree</last_name>
      <phone>901-515-4524</phone>
      <email>kacree@uthsc.edu</email>
    </contact>
    <investigator>
      <last_name>Amber Thacker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HD Research (Memorial Hermann - Memorial City Medical Center)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katelyn Freeman</last_name>
      <phone>361-728-5693</phone>
      <email>kfreeman@lotuscr.com</email>
    </contact>
    <contact_backup>
      <last_name>Diego Rodriguez</last_name>
      <phone>361-728-5693</phone>
      <email>drodriguez@lotuscr.com</email>
    </contact_backup>
    <investigator>
      <last_name>Alan Skolnick</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HD Research (Memorial Hermann Southeast Hospital)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Staci Maroney</last_name>
      <phone>714-480-3028</phone>
      <email>smaroney@lotuscr.com</email>
    </contact>
    <investigator>
      <last_name>Adnan Rafiq</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Layla Amjad</last_name>
      <phone>713-484-6947</phone>
      <email>lamjad@ctntexas.com</email>
    </contact>
    <investigator>
      <last_name>Sangeetha Vulichi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital De Alta Compleijdad Cuenca Alta Nestor Kirchner</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1814</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ayelen López- Sansón</last_name>
      <phone>54 9 1161418286</phone>
      <email>ayelenlopezsanson@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Javier Farina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Bicentenario de Esteban Echeverría</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1942DOL</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Russo, MD</last_name>
      <phone>54 9 1140252708</phone>
      <email>adrianarusso.sc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Nicolás Caminiti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center Sagrado Corazon</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1039AAC</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pedro Marin</last_name>
      <phone>54 91164698656</phone>
      <email>pedromarin.hematologia@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Martin Dobarro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanatorio Güemes</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1180ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian F Sorrentino</last_name>
      <phone>54 9 1130396596</phone>
      <email>jsorrentino@fsg.edu.ar</email>
    </contact>
    <investigator>
      <last_name>Anselmo Bertetti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital De Infecciosas &quot;Dr. Francisco Javier Muniz&quot;</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1282AEL</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula V Cini</last_name>
      <phone>54 91132623906</phone>
      <email>p.cini@buenosaires.gob.ar</email>
    </contact>
    <investigator>
      <last_name>Carlos Alberto Gonzalaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacao Pio XII - Hospital de Amor de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>Sao Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruna Souza</last_name>
      <phone>55 17 3321 66</phone>
      <phone_ext>6637</phone_ext>
      <email>bruna.roberti@hcancerbarretos.com.br</email>
    </contact>
    <investigator>
      <last_name>Paulo de Tarso Oliveira e Castro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital PUC Campinas</name>
      <address>
        <city>Campinas</city>
        <state>Sao Paulo</state>
        <zip>13060-904</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leticia Oliveira</last_name>
      <phone>55 19 3343-8511</phone>
      <email>leticiaoliveira@uol.com.br</email>
    </contact>
    <investigator>
      <last_name>Marina Patelli Souza Lima</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina de Botucatu - UNESP</name>
      <address>
        <city>Botucatu</city>
        <zip>18618-687</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luana Pagan</last_name>
      <phone>55 143 880 1001</phone>
      <email>luanapagan@alunos.fmb.unesp.br</email>
    </contact>
    <investigator>
      <last_name>Bertha Furlan Polegato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário São Francisco na Providencia de Deus</name>
      <address>
        <city>Bragança Paulista</city>
        <zip>12916-542</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Tavares de Souza</last_name>
      <phone>55(11)99513-4554</phone>
      <email>jessicatsouza04@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Murillo Antunes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IPECC (Instituto De Pesquisa Clínica de Campinas)</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Vicente</last_name>
      <phone>55 19 3267-0023</phone>
      <email>carla@ipecc.com.br</email>
    </contact>
    <investigator>
      <last_name>José Saraiva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sociedade Hospital Angelina Caron</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Sehnem</last_name>
      <phone>55-41-3679-8783</phone>
      <email>elianesehnem@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dalton Bertolin Precoma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Curitiba</name>
      <address>
        <city>Curitiba</city>
        <zip>80010-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Verônica Barros</last_name>
      <phone>55 41 3362 6633</phone>
      <email>pesquisaclinica2@cepeti.com.br</email>
    </contact>
    <investigator>
      <last_name>Álvaro Rea-Neto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalar de Niteroi</name>
      <address>
        <city>Niteroi</city>
        <zip>24020-096</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clarissa de Assumpção</last_name>
      <phone>55 21 2729 1000 x 8205</phone>
      <email>cassumpcao@chniteroi.com.br</email>
    </contact>
    <investigator>
      <last_name>Natalia Chilinque Zambao da Silva</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre - Infectologia - Centro de Pesquisa Clínica</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura De Bona</last_name>
      <phone>55 513 359 6331</phone>
      <email>lauradbona@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Eduardo Sprinz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Luca Da PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Bueno</last_name>
      <phone>51 3320 5120</phone>
      <email>nataliallbueno@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Paulo Caramori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Cementino Fraga Filho</name>
      <address>
        <city>Rio De Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Conceição dos Santos</last_name>
      <phone>55 (021) 3938-2904</phone>
      <email>carla@idt.ufrj.br</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Stankiewicz Machado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IDOR - D'Or Institute for Research and Education</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04501-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renata Lopes</last_name>
      <phone>55 (11) 2109 8800</phone>
      <email>renata.lopes@idor.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Wagner Santos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Incor - Instituto do Coração do Hospital das Clínicas da FMUSP</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriella S Ayub de Mendonça</last_name>
      <phone>55 11 2661-5109</phone>
      <email>gabriellaayubm@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ludhmila Hajjar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica de Alergia Martti Antila S/S LTDA</name>
      <address>
        <city>Sorocaba</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priscilla Oliveira</last_name>
      <phone>55 (15) 3519-4912</phone>
      <email>priscilla.goes@alergiaclinica.com.br</email>
    </contact>
    <investigator>
      <last_name>Martti Antila</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundação Faculdade Regional de Medicina de São José do Rio Preto</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Centurione</last_name>
      <phone>55 17 3201-5054</phone>
      <email>annacenturione.cip@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Suzana Lobo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MHAT Blagoevgrad AD Department of Infectious Diseases</name>
      <address>
        <city>Blagoevgrad</city>
        <zip>2700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irina Margina</last_name>
      <phone>00359 892 226 028</phone>
      <email>blagoevgrad@rdservices.org</email>
    </contact>
    <investigator>
      <last_name>Mustafa Uzunov</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleksander Vakshinski</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Haskovo, Department of Infectious Diseases</name>
      <address>
        <city>Haskovo</city>
        <zip>6304</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veselina Stileva</last_name>
      <phone>00359 892 226 067</phone>
      <email>v.stileva@rdservices.org</email>
    </contact>
    <contact_backup>
      <last_name>Mariya Ivanova</last_name>
      <phone>00359 988 881 872</phone>
      <email>m.ivanova@rdservices.org</email>
    </contact_backup>
    <investigator>
      <last_name>Krasimira Kinova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Dr. Atanas Dafovski AD, Kardzhali, Department of Pneumology and Phthisiatry, Dept. of Pneumology &amp; Phthisiatry</name>
      <address>
        <city>Kardzhali</city>
        <zip>6600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vanya Vlaseva</last_name>
      <phone>00359 888 887 625</phone>
      <email>vanya.vlaseva@pratia.com</email>
    </contact>
    <contact_backup>
      <last_name>Violeta Yordanova</last_name>
      <phone>00359 882 056 605</phone>
      <email>violeta.yordanova@cru-smo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Diana Valcheva-Kuzmanova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Specialized hospital for active treatment of pulmonary diseases -Pernik EOOD, Pernik</name>
      <address>
        <city>Pernik</city>
        <zip>2300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorita Strahilova</last_name>
      <phone>00 359 884897734</phone>
      <email>pernik@rdservices.org</email>
    </contact>
    <contact_backup>
      <last_name>Neli Chakova</last_name>
      <phone>00 359 892226034</phone>
      <email>n.chakova@rdservices.org</email>
    </contact_backup>
    <investigator>
      <last_name>Boyko Boyanov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Pulmed&quot; OOD Plovid Rheumatology</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kostadin Savov, MD</last_name>
      <phone>00359 887 411417</phone>
      <email>kostadinsavov@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lyubomir Sapundzhiev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MHAT Bratan Shukerov,Pulmonology Department</name>
      <address>
        <city>Smolyan,</city>
        <zip>4700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Grigor Lalov, MD</last_name>
      <phone>00359 889 218 608</phone>
      <email>grilow884@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Grigor Lalov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Tsaritsa Yoanna-ISUL&quot; EAD, Sofia,</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Boryana Todorova</last_name>
      <phone>00 359 898 585395</phone>
      <email>m_b_green@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Petar Kalaydzhiev</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment and Emergency Medicine</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gergana Paunova</last_name>
      <phone>00359 892 226 012</phone>
      <email>g.paunova@rdservices.org</email>
    </contact>
    <contact_backup>
      <last_name>Mariya Nikova</last_name>
      <phone>00359 892 226 032</phone>
      <email>m.nikova@rdservices.org</email>
    </contact_backup>
    <investigator>
      <last_name>Diana Mladenova</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Dimitrova</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment- Knyaginya Klementina - Sofia EAD, Sofia, Department of Pneumology</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariana Yankulova</last_name>
      <phone>00359 898 416 424</phone>
      <email>myankulova@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Mariana Yankulova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Professor Doctor Stoyan Kirkovich&quot; AD, Stara Zagora, Clinic of Anaestheology and intensive care</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadezhda Trungova</last_name>
      <phone>+359885004773</phone>
      <email>nadezhda.trungova@clineca.ne</email>
    </contact>
    <contact_backup>
      <last_name>Vesela Peykova</last_name>
      <phone>00359 88 248 5424</phone>
      <email>vesela.peykova@clineca.net</email>
    </contact_backup>
    <investigator>
      <last_name>Georgi Arabadzhiev</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lilia Pekova</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación Hospital Universidad del Norte (Barranquilla)</name>
      <address>
        <city>Atlántico</city>
        <zip>080001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Osmith Amaya</last_name>
      <phone>57 300 753 4456</phone>
      <email>osmitha@uninorte.edu.co</email>
    </contact>
    <investigator>
      <last_name>Hugo Macareno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa (Barranquilla)</name>
      <address>
        <city>Barranquilla</city>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrés Cadena</last_name>
      <phone>57 3369999</phone>
      <email>factibilidad@clinicadelacosta.co</email>
    </contact>
    <investigator>
      <last_name>Leonardo Brochado Fontalvo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion Santa Fe de Bogota</name>
      <address>
        <city>Bogotá</city>
        <zip>111311</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>José A de la Hoz, MD</last_name>
      <phone>57 603 0303</phone>
      <email>jose.delahoz@fsfb.org.co</email>
    </contact>
    <investigator>
      <last_name>Jairo Roa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundación Cardioinfantil-Instituto de Cardiología</name>
      <address>
        <city>Bogotá</city>
        <zip>111311</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eva Quiro</last_name>
      <phone>+576672727</phone>
      <email>evaquiro@cardioinfantil.org</email>
    </contact>
    <investigator>
      <last_name>Fabio Varón-Vega</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Medico Imbanaco de Cali S.A</name>
      <address>
        <city>Cali</city>
        <zip>760042</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jose Oñate</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Corporación para Estudios en Salud - CES</name>
      <address>
        <city>Medellín</city>
        <zip>050032</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Veronica Posada</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sociedad Medica Rionegro- Clínica Somer (Rionegro)</name>
      <address>
        <city>Rionegro</city>
        <zip>050023</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Madrid</last_name>
      <phone>3004518248</phone>
      <email>cmadrid@clinicasomer.com</email>
    </contact>
    <contact_backup>
      <last_name>Valentina Aranzazu</last_name>
    </contact_backup>
    <investigator>
      <last_name>Alfredo Herrnandez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unidad Médica para la Salud Integral (UMSI)</name>
      <address>
        <city>San Nicolas de los Garza</city>
        <state>Nuevo Leon</state>
        <zip>66465</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Héctor Carreón Segoviano</last_name>
      <phone>(52) 81 2385 3248</phone>
      <email>hectorcarreon2000@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rodolfo Posadas-Valay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Culiacán</name>
      <address>
        <city>Culiacán</city>
        <zip>80230</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nora Mendoza</last_name>
      <phone>(52) 667 721 53 55</phone>
      <email>nora.mendoza@sinacor.org</email>
    </contact>
    <investigator>
      <last_name>Jorge Zamudio Lerma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General de Occidente</name>
      <address>
        <city>Zapopan</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Moran Velaquez</last_name>
      <phone>(52) 33 19 83 01 58</phone>
      <email>emoran@etcurae.com</email>
    </contact>
    <investigator>
      <last_name>Raul Baptista-Rosas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

